Anthropic Wins Preliminary Injunction in Department of Defense Fight 3/27/26

A rich life isn't a straight line to a destination on the horizon.

Sometimes it takes an unexpected turn with detours, new possibilities, and even another passenger,

who are three, and with 100 years of navigating ups and downs, you can count on Edward Jones to

help guide you through it all because life is a winding path made rich by the people you walk

it with. Let's find your rich together, Edward Jones, member SIPC.

Before we had AT&T business wireless coverage, our delivery GPS wasn't the most reliable.

Once our driver had to do a 14 point turn to get back on route, a 14 point turn,

an influencer even live-streamed the whole thing. Not good for business. Now with AT&T business wireless,

routes are updating on the fly and deliveries are on time. And the influencer did get us 53 new followers

though, AT&T business wireless. Connecting changes everything.

The government now has seven days to appeal before it takes effect. To be clear, the judge

is not ordering the Pentagon to keep using cloth, and she's also not handing anthropic control

over how its tech is used by the military. The government remains free to stop using anthropic

and switch to another AI vendor. In the 43-page order, the judge writes that the government's

actions don't appear tied to its stated national security interests at all, but instead look

designed to punish anthropic for criticizing the government's contracting position in the press.

For now, her ruling restores the status quo to February 27th before the directives were issued.

That means that the freeze applies not just to the Pentagon action, but also to the president's

government-wide ban covering 17 agencies, including NASA and the SEC, that had been moving to

cut ties with the anthropic. The legal fight now shifts to Washington, whereas here are the

cases about constitutional claims, protected speech, and due process. In DC, the question is whether

the administration stretched a law meant for foreign adversary contractors far beyond its intended

use. We're expecting a decision from that panel of three judges, imminently, and if they find,

in favor of the government, enforcement could get messy, fast, leaving in limbo, enterprise

customers, and defense contractors like Palantir that have built critical workflows with Claude Code.

Guys, it's also a question for this IPO, and there's now reports that it could be coming as soon

as October. I wonder if the legal proceedings here are going to be worked out by then, and ultimately

then what they're going to be able to tell investors about what that means for their business.

Precisely, so if this hold on the designation remains intact, that could last for months while

this court case plays out, which would be ostensibly a good thing for the IPO. A lot of these clients

and customers who had to unwind the use of Claude Code could continue to use it while this plays

out in court. What to me is the hardest part of this online is really Palantir because they use

multiple models, but right now they're maven smart system, the platform that's for military

intelligence analysis and weapons targeting. It has multiple prompts and workflows built using

Claude Code specifically, so there's just so many questions about the logistics of pulling

anthropics tech out of these products. Yeah, well, see if that'll be necessary. McKenzie, thank you very

much. Snoring, gasping during sleep, feeling fatigued, wake up to Zeppbound, to Zeppatide.

The first and only FDA approved prescription medicine for moderate to severe obstructive

sleep apnea, OSA, and adults with obesity. Zeppound is an injectable prescription medicine that

may help adults with moderate to severe obstructive sleep apnea, OSA, and obesity to improve their OSA.

Zeppound should be used with a reduced calorie diet and increased physical activity. Zeppound

is approved as a 2.5, 5, 7.5, 10, 12.5, or 15 milligram injection. Zeppound contains

tersepatide and should not be used with other tersepatide-containing products or any GLP-1

receptor agonist medicines. It is not known if Zeppound is safe and effective for use in children.

Do not share needles or pens or reuse needles. Don't take Zeppound if allergic to it,

or if you or someone in your family had medullary thyroid cancer or multiple endocrine

neoplasia syndrome type 2. Tell your doctor if you get a lump or swelling in your neck. Stop

Zeppound and call your doctor if you have severe stomach pain or a serious allergic reaction.

Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if

you experience vision changes, depression, or suicidal thoughts before schedule procedures with

anesthesia. If you're nursing, pregnant, planned to be or taking birth control pills.

Taking Zeppound with a sulfonoluria or insulin may cause a little blood sugar. Side effects

include nausea, diarrhea, and vomiting, which can cause dehydration and worsen kidney problems.

Talk to your doctor, call 1-800-545-5979 or visit Zeppound.lily.com.

Zeppound and its delivery device base in QuickPin are registered trademarks owned or licensed by

Eli Lilly and company. It's subsidiaries or affiliates.